Bibliographic Details
| Title: |
Developing patient-derived organoids to demonstrate JX24120 inhibits SAMe synthesis in endometrial cancer by targeting MAT2B |
| Authors: |
Chunxue Zhang, Xiaojing Lu, Ting Ni, Qi Wang, Xiaoyan Gao, Xiao Sun, Jian Li, Fei Mao, Jin Hou, Yudong Wang |
| Source: |
Pharmacological Research, Vol 209, Iss , Pp 107420- (2024) |
| Publisher Information: |
Elsevier, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Therapeutics. Pharmacology |
| Subject Terms: |
Endometrial cancer, MAT2B, Patient-derived organoid, JX24120, chlorpromazine derivative, S-adenosylmethionine, Therapeutics. Pharmacology, RM1-950 |
| More Details: |
Endometrial cancer (EC) is one of the most common gynecologic malignancies, which lacking effective drugs for intractable conditions or patients unsuitable for surgeries. Recently, the patient-derived organoids (PDOs) are found feasible for cancer research and drug discoveries. Here, we have successfully established a panel of PDOs from EC and conducted drug repurposing screening and mechanism analysis for cancer treatment. We confirmed that the regulatory β subunit of methionine adenosyltransferase (MAT2B) is highly correlated with malignant progression in endometrial cancer. Through drug screening on PDOs, we identify JX24120, chlorpromazine derivative, as a specific inhibitor for MAT2B, which directly binds to MAT2B (Kd = 4.724 μM) and inhibits the viability of EC PDOs and canonical cell lines. Correspondingly, gene editing assessment demonstrates that JX24120 suppresses tumor growth depending on the presence of MAT2B in vivo and in vitro. Mechanistically, JX24120 induces inhibition of S-adenosylmethionine (SAMe) synthesis, leading to suppressed mTORC1 signaling, abnormal energy metabolism and protein synthesis, and eventually apoptosis. Taken together, our study offers a novel approach for drug discovery and efficacy assessment by using the PDOs models. These findings suggest that JX24120 may be a potent MAT2B inhibitor and will hopefully serve as a prospective compound for endometrial cancer therapy. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1096-1186 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S1043661824003657; https://doaj.org/toc/1096-1186 |
| DOI: |
10.1016/j.phrs.2024.107420 |
| Access URL: |
https://doaj.org/article/5b5263634eab4fd884def3dd24776dae |
| Accession Number: |
edsdoj.5b5263634eab4fd884def3dd24776dae |
| Database: |
Directory of Open Access Journals |
